Polymyalgia rheumatica: 125 years of progress?

Rooney, P. J.; Rooney, Jennifer; Bálint, Géza; Bálint, Péter

doi:10.1177/0036933014548144

Cited by 6 publications

(8 citation statements)

References 85 publications

(181 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is considerable clinical and some immunogenetic overlap between GCA and PMR, with co-occurrence being almost 40 times more likely than would be expected if they were truly separate syndromes [14,15]. The precise nature of their relationship remains to be clarified and although there are distinct differences [16,17], the presence of PMR should alert clinicians to the possibility of GCA.…”

Section: Symptomsmentioning

confidence: 99%

Giant cell arteritis: ophthalmic manifestations of a systemic disease

Smit

O’Sullivan

Mackey

et al. 2016

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Symptomsmentioning

confidence: 99%

Giant cell arteritis: ophthalmic manifestations of a systemic disease

Smit

O’Sullivan

Mackey

et al. 2016

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Giant cell arteritis (GCA) incidence is highest in populations with Scandinavian ancestry [ 6 – 8 ] and this has led to suggestions that this might be due to genetic factors [ 9 , 10 ]. Susceptibility to GCA has been reported to be associated with carriage of HLA-DRB1 *04, but not all studies have shown an association and there are conflicting data as to whether there is an association with specific HLA-DRB1 *04 alleles [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation

et al. 2015

View full text Add to dashboard Cite

IntroductionGiant cell arteritis (GCA) is an autoimmune disease commonest in Northern Europe and Scandinavia. Previous studies report various associations with HLA-DRB1*04 and HLA-DRB1*01; HLA-DRB1 alleles show a gradient in population prevalence within Europe. Our aims were (1) to determine which amino acid residues within HLA-DRB1 best explained HLA-DRB1 allele susceptibility and protective effects in GCA, seen in UK data combined in meta-analysis with previously published data, and (2) to determine whether the incidence of GCA in different countries is associated with the population prevalence of the HLA-DRB1 alleles that we identified in our meta-analysis.MethodsGCA patients from the UK GCA Consortium were genotyped by using single-strand oligonucleotide polymerization, allele-specific polymerase chain reaction, and direct sequencing. Meta-analysis was used to compare and combine our results with published data, and public databases were used to identify amino acid residues that may explain observed susceptibility/protective effects. Finally, we determined the relationship of HLA-DRB1*04 population carrier frequency and latitude to GCA incidence reported in different countries.ResultsIn our UK data (225 cases and 1378 controls), HLA-DRB1*04 carriage was associated with GCA susceptibility (odds ratio (OR) = 2.69, P = 1.5×10−11), but HLA-DRB1*01 was protective (adjusted OR = 0.55, P = 0.0046). In meta-analysis combined with 14 published studies (an additional 691 cases and 4038 controls), protective effects were seen from HLA-DR2, which comprises HLA-DRB1*15 and HLA-DRB1*16 (OR = 0.65, P = 8.2×10−6) and possibly from HLA-DRB1*01 (OR = 0.73, P = 0.037). GCA incidence (n = 17 countries) was associated with population HLA-DRB1*04 allele frequency (P = 0.008; adjusted R2 = 0.51 on univariable analysis, adjusted R2 = 0.62 after also including latitude); latitude also made an independent contribution.ConclusionsWe confirm that HLA-DRB1*04 is a GCA susceptibility allele. The susceptibility data are best explained by amino acid risk residues V, H, and H at positions 11, 13, and 33, contrary to previous suggestions of amino acids in the second hypervariable region. Worldwide, GCA incidence was independently associated both with population frequency of HLA-DRB1*04 and with latitude itself. We conclude that variation in population HLA-DRB1*04 frequency may partly explain variations in GCA incidence and that HLA-DRB1*04 may warrant investigation as a potential prognostic or predictive biomarker.Electronic supplementary materialThe online version of this article (doi:10.1186/s13075-015-0692-4) contains supplementary material, which is available to authorized users.

show abstract

“…Polymyalgia Rheumatica (PMR), a common inflammatory condition of elderly people [12], is characterized by pain in both shoulders and hips, elevated acute-phase reactants and a prompt response to corticosteroid therapy [13]. With these clinical features lacking specificity, it is often difficult to diagnose or classify subjects suspected of PMR [14].…”

Section: Polymyalgia Rheumaticamentioning

confidence: 99%

Is ultrasound changing the way we understand rheumatology? Including ultrasound examination in the classification criteria of polymyalgia rheumatica and gout.

Codreanu¹,

Enache²

2015

Med Ultrason

View full text Add to dashboard Cite

Ultrasonography (US) is widely used in the diagnosis of rheumatic conditions, and its value for the classification criteria of rheumatic diseases has been recently suggested. According to the EULAR/ACR provisional criteria for polymyalgia rheumatica, adding US to the clinical and serological features will significantly improve the sensitivity of proposed criteria. The ability of high resolution US to detect crystalline deposits of monosodium urate in joints and soft tissues is well recognized. For the first time, the new 2014 ACR/EULAR set of proposed criteria for gout includes advanced imaging techniques for the detection of disease: US and dual-energy computed tomography. Due to low costs and affordability, use of US evaluation for patients with suspected gout will increase both specificity and sensibility of classification criteria. The recent inclusion of US in the classification criteria of various rheumatic diseases, such as PMR and gout, implies that this imaging technique is not only useful as a valued diagnostic tool for individual cases, but also on a larger scale, it will improve doctors' ability to classify diseases. Its use is thus changing our understanding of rheumatic diseases allowing further advances in research and clinical practice.

show abstract

Polymyalgia rheumatica: 125 years of progress?

Cited by 6 publications

References 85 publications

Giant cell arteritis: ophthalmic manifestations of a systemic disease

Giant cell arteritis: ophthalmic manifestations of a systemic disease

Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation

Is ultrasound changing the way we understand rheumatology? Including ultrasound examination in the classification criteria of polymyalgia rheumatica and gout.

Contact Info

Product

Resources

About